The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...